• Japanese
  • Korean
  • Chinese
Cover Image

Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Abstract

Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market. The report identifies the key trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Acute Respiratory Distress Syndrome (ARDS) Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Acute Respiratory Distress Syndrome (ARDS) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Acute Respiratory Distress Syndrome (ARDS) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market landscape? - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Acute Respiratory Distress Syndrome Therapeutics - Introduction 7

  • 2.1 Overview 7
  • 2.2 Normal Functioning of Lungs 7
  • 2.3 Epidemiology 8
    • 2.3.1 Incidence 8
    • 2.3.2 Mortality 9
    • 2.3.3 Quality of Life 10
  • 2.4 Etiology and Pathophysiology 10
    • 2.4.1 Progression of Acute Respiratory Distress Syndrome 12
  • 2.5 Symptoms 13
  • 2.6 Complications Associated with Acute Respiratory Distress Syndrome 13
  • 2.7 Diagnosis of Acute Respiratory Distress Syndrome 14
    • 2.7.1 Laboratory Tests 14
    • 2.7.2 Radiography 14
    • 2.7.3 Computed Tomography (CT) 14
    • 2.7.4 Invasive Hemodynamic Monitoring 14
    • 2.7.5 Echocardiography 14
    • 2.7.6 Bronchoscopy 15
  • 2.8 Treatment 16
    • 2.8.1 Ventilation Strategy 17
    • 2.8.2 Prone Positioning 18
    • 2.8.3 Hemodynamic Management 18
    • 2.8.4 Extracorporeal Lung Support 18
    • 2.8.5 Pharmacological Therapies 18
  • 2.9 Referral Pathway 21
  • 2.10 GlobalData Pipeline Report Guidance 23

3 Acute Respiratory Distress Syndrome Therapeutics - Market Characterization 24

  • 3.1 Overview 24
  • 3.2 Acute Respiratory Distress Syndrome Therapeutics Market Size (2006-2011) -Global 24
  • 3.3 Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2011-2019) - Global 26
  • 3.4 Acute Respiratory Distress Syndrome Therapeutics Market Size (2006-2011) - The US 28
  • 3.5 Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2011-2019) - The US 29
  • 3.6 Acute Respiratory Distress Syndrome Therapeutics Market Size (2006-2011) - France 30
  • 3.7 Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2011-2019) - France 31
  • 3.8 Acute Respiratory Distress Syndrome Therapeutics Market Size (2006-2011) - Germany 32
  • 3.9 Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2011-2019) - Germany 33
  • 3.10 Acute Respiratory Distress Syndrome Therapeutics Market Size (2006-2011) - Italy 34
  • 3.11 Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2011-2019) - Italy 35
  • 3.12 Acute Respiratory Distress Syndrome Therapeutics Market Size (2006-2011) - Spain 36
  • 3.13 Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2011-2019) - Spain 37
  • 3.14 Acute Respiratory Distress Syndrome Therapeutics Market Size (2006-2011) - The UK 38
  • 3.15 Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2011-2019) - The UK 39
  • 3.16 Acute Respiratory Distress Syndrome Therapeutics Market Size (2006-2011) - Japan 40
  • 3.17 Acute Respiratory Distress Syndrome Therapeutics Market Forecast (2011-2019) - Japan 41
  • 3.18 Drivers and Barriers for the Acute Respiratory Distress Syndrome Therapeutics Market 42
    • 3.18.1 Drivers for the Acute Respiratory Distress Syndrome Therapeutics Market 42
    • 3.18.2 Barriers for the Acute Respiratory Distress Syndrome Market 42
  • 3.19 Opportunity and Unmet Need 43
  • 3.20 Key Takeaway 43

4 Acute Respiratory Distress Syndrome Therapeutics - Competitive Assessment 44

  • 4.1 Overview 44
  • 4.2 Strategic Competitor Assessment 44
  • 4.3 Product Profiles for the Major Marketed Products in the Acute Respiratory Distress Syndrome Therapeutics Market 44
    • 4.3.1 Elaspol 100 (sivelestat sodium hydrate) 44
  • 4.4 Key Takeaway 45

5 Acute Respiratory Distress Syndrome Therapeutics - Pipeline Assessment 46

  • 5.1 Overview 46
  • 5.2 Strategic Pipeline Assessment 46
  • 5.3 Acute Respiratory Distress Syndrome Therapeutics Pipeline - Pipeline by Phases of Development 46
    • 5.3.1 Acute Respiratory Distress Syndrome Therapeutics - Phase III Pipeline 47
    • 5.3.2 Acute Respiratory Distress Syndrome Therapeutics - Phase II Pipeline 47
    • 5.3.3 Acute Respiratory Distress Syndrome Therapeutics - Phase I/II Pipeline 47
    • 5.3.4 Acute Respiratory Distress Syndrome Therapeutics - Phase I Pipeline 47
    • 5.3.5 Acute Respiratory Distress Syndrome Therapeutics - Preclinical 48
  • 5.4 Acute Respiratory Distress Syndrome Therapeutics, Technology Trends Analytical Framework 48
  • 5.5 Acute Respiratory Distress Syndrome Therapeutics Market - Pipeline by Mechanism of Action 50
  • 5.6 Molecule Profile for Late Stage Products Under Clinical Development 51
    • 5.6.1 ALT-836 51
    • 5.6.2 FP-1201 51
    • 5.6.3 SB-681323 52
  • 5.7 Key Takeaway 52

6 Acute Respiratory Distress Syndrome Therapeutics - Clinical Trials Mapping 53

  • 6.1 Clinical Trial Mapping Overview 53
  • 6.2 Clinical Trials by Country (the US, EU5 and Japan) 53
  • 6.3 Clinical Trials by Phase 54
  • 6.4 Clinical Trials by Trial Status 55
  • 6.5 Overall Sponsors 56
  • 6.6 Prominent Sponsors 57
  • 6.7 Top Companies Participating in Acute Respiratory Distress Syndrome Therapeutics Clinical Trials 58

7 Acute Respiratory Distress Syndrome Therapeutics - Strategic Assessment 59

  • 7.1 Key Events Impacting the Future Market 59
  • 7.2 Acute Respiratory Distress Syndrome Therapeutics: Implications for Future Market Competition 60

8 Acute Respiratory Distress Syndrome Therapeutics - Future Players in the Market 61

  • 8.1 Introduction 61
    • 8.1.1 GlaxoSmithKline 61
    • 8.1.2 Altor BioSciences 64
    • 8.1.3 Faron Pharmaceuticals, Ltd. 65
    • 8.1.4 Mondobiotech 65

9 Acute Respiratory Distress Syndrome - Licensing and Partnership Deals 67

10 Acute Respiratory Distress Syndrome Therapeutics - Appendix 68

  • 10.1 Definitions 68
  • 10.2 Acronyms 68
  • 10.3 Bibliography 69
  • 10.4 Research Methodology 69
    • 10.4.1 Coverage 70
    • 10.4.2 Secondary Research 70
    • 10.4.3 Forecasting 70
    • 10.4.4 Primary Research 73
    • 10.4.5 Expert Panel Validation 74
  • 10.5 Contact Us 74
  • 10.6 Disclaimer 74

List of Tables

1.1 List of Tables

  • Table 1: Incidence Pool of Acute Respiratory Distress Syndrome in Seven Major Markets 8
  • Table 2: Causes of Acute Respiratory Distress Syndrome 11
  • Table 3: Current Therapeutic Strategies Available for the Management of Patients with Acute Respiratory Distress Syndrome 20
  • Table 4: Acute Respiratory Distress Syndrome Therapeutics Market, Global, Revenue ($m), 2006-2011 25
  • Table 5: Acute Respiratory Distress Syndrome Therapeutics Market, Global, Forecast ($m), 2011-2019 27
  • Table 6: Acute Respiratory Distress Syndrome Therapeutics Market, The US, Revenue ($m), 2006-2011 28
  • Table 7: Acute Respiratory Distress Syndrome Therapeutics Market, The US, Forecasts ($m), 2011-2019 29
  • Table 8: Acute Respiratory Distress Syndrome Therapeutics Market, France, Revenue ($m), 2006-2011 30
  • Table 9: Acute Respiratory Distress Syndrome Therapeutics Market, France, Forecasts ($m), 2011-2019 31
  • Table 10: Acute Respiratory Distress Syndrome Therapeutics Market, Germany, Revenue ($m), 2006-2011 32
  • Table 11: Acute Respiratory Distress Syndrome Therapeutics Market, Germany, Forecasts ($m), 2011-2019 33
  • Table 12: Acute Respiratory Distress Syndrome Therapeutics Market, Italy, Revenue ($m), 2006-2011 34
  • Table 13: Acute Respiratory Distress Syndrome Therapeutics Market, Italy, Forecasts ($m), 2011-2019 35
  • Table 14: Acute Respiratory Distress Syndrome Therapeutics Market, Spain, Revenue ($m), 2006-2011 36
  • Table 15: Acute Respiratory Distress Syndrome Therapeutics Market, Spain, Forecasts ($m), 2011-2019 37
  • Table 16: Acute Respiratory Distress Syndrome Therapeutics Market, The UK, Revenue ($m), 2006-2011 38
  • Table 17: Acute Respiratory Distress Syndrome Therapeutics Market, The UK, Forecasts ($m), 2011-2019 39
  • Table 18: Acute Respiratory Distress Syndrome Therapeutics Market, Japan, Revenue ($m), 2006-2011 40
  • Table 19: Acute Respiratory Distress Syndrome Therapeutics Market, Japan, Forecasts ($m), 2011-2019 41
  • Table 20: All Deaths Occurring Within 180 Days from the Initiation of Study Drug Infusion in Phase III Double Blind Study (Number of Deaths) 45
  • Table 21: Acute Respiratory Distress Syndrome Therapeutics - Phase II Pipeline, 2012 47
  • Table 22: Acute Respiratory Distress Syndrome Therapeutics - Phase I/II Pipeline, 2012 47
  • Table 23: Acute Respiratory Distress Syndrome Therapeutics - Phase I Pipeline, 2012 47
  • Table 24: Acute Respiratory Distress Syndrome Therapeutics - Preclinical Pipeline, 2012 48
  • Table 25: Acute Respiratory Distress Syndrome Therapeutics - Clinical Trials by Country, 2012 53
  • Table 26: Acute Respiratory Distress Syndrome Therapeutics - Clinical Trials by Phase, 2012 54
  • Table 27: Acute Respiratory Distress Syndrome Therapeutics - Clinical Trials by Status, 2012 55
  • Table 28: Acute Respiratory Distress Syndrome Therapeutics, Overall Sponsors, 2012 56
  • Table 29: Acute Respiratory Distress Syndrome Therapeutics - Prominent Sponsors, 2012 57
  • Table 30: Acute Respiratory Distress Syndrome Therapeutics - Top Companies Participating in Clinical Trials, 2012 58
  • Table 31: GlaxoSmithKline, Respiratory Disease Pipeline, 2012 63
  • Table 32: GlaxoSmithKline, Acute Respiratory Distress Syndrome Pipeline, 2012 64
  • Table 33: Altor BioSciences, Acute Respiratory Distress Syndrome, Pipeline, 2012 64
  • Table 34: Faron Pharmaceuticals, Acute Respiratory Distress Syndrome Pipeline, 2012 65
  • Table 35: Mondobiotech, Acute Respiratory Distress Syndrome Therapeutics Pipeline, 2012 66
  • Table 36: Acute Respiratory Distress Syndrome Therapeutics: Global, Licensing and Partnership Deals 2009-2011 67

List of Figures

1.2 List of Figures

  • Figure 1: Acute Respiratory Distress Syndrome, Affected Lung With Enlarged Alveoli 7
  • Figure 2: Key Opinion Leader Insights, Incidence of Acute Respiratory Distress Syndrome in the US, the UK and Japan 8
  • Figure 3: Key Opinion Leader Insights, Mortality of Acute Respiratory Distress Syndrome in the US, the UK and Japan 9
  • Figure 4: ICU Mortality Rate in Acute Respiratory Distress Syndrome 9
  • Figure 5: Pathophysiology of Acute Respiratory Distress Syndrome 10
  • Figure 6: Breakdown of Various Conditions Leading to Acute Respiratory Distress Syndrome 11
  • Figure 7: Time Course for the Development and Resolution of Acute Respiratory Distress Syndrome 12
  • Figure 8: Complications Associated with Acute Respiratory Distress Syndrome 13
  • Figure 9: Lung Biopsy of Acute Respiratory Distress Syndrome Patients 15
  • Figure 10: Key Opinion Leader Insights, Diagnosis of Acute Respiratory Distress Syndrome in the US, the UK and Japan 15
  • Figure 11: Treatment Algorithm for Acute Respiratory Distress Syndrome 16
  • Figure 12: Key Opinion Leader Insights, Treatment of Acute Respiratory Distress Syndrome in the US, the UK and Japan 19
  • Figure 13: Referral Pathway 21
  • Figure 14: Key Opinion Leader Insights, Referral Pathway for Acute Respiratory Distress Syndrome in the US, the UK and Japan 22
  • Figure 15: Acute Respiratory Distress Syndrome Therapeutics Market, Global, Revenue ($m), 2006-2011 24
  • Figure 16: Acute Respiratory Distress Syndrome Therapeutics Market, Global, Forecast ($m), 2011-2019 26
  • Figure 17: Acute Respiratory Distress Syndrome Therapeutics Market, the US, Revenue ($m), 2006-2011 28
  • Figure 18: Acute Respiratory Distress Syndrome Therapeutics Market, The US, Forecast ($m), 2011-2019 29
  • Figure 19: Acute Respiratory Distress Syndrome Therapeutics Market, France, Revenue ($m), 2006-2011 30
  • Figure 20: Acute Respiratory Distress Syndrome Therapeutics Market, France, Forecast ($m), 2011-2019 31
  • Figure 21: Acute Respiratory Distress Syndrome Therapeutics Market, Germany , Revenue ($m), 2006-2011 32
  • Figure 22: Acute Respiratory Distress Syndrome Therapeutics Market, Germany , Forecast ($m), 2011-2019 33
  • Figure 23: Acute Respiratory Distress Syndrome Therapeutics Market, Italy, Revenue ($m), 2006-2011 34
  • Figure 24: Acute Respiratory Distress Syndrome Therapeutics Market, Italy, Forecast ($m), 2011-2019 35
  • Figure 25: Acute Respiratory Distress Syndrome Therapeutics Market, Spain, Revenue ($m), 2006-2011 36
  • Figure 26: Acute Respiratory Distress Syndrome Therapeutics Market, Spain, Forecast ($m), 2011-2019 37
  • Figure 27: Acute Respiratory Distress Syndrome Therapeutics Market, The UK, Revenue ($m), 2006-2011 38
  • Figure 28: Acute Respiratory Distress Syndrome Therapeutics Market, The UK, Forecasts ($m), 2011-2019 39
  • Figure 29: Acute Respiratory Distress Syndrome Therapeutics Market, Japan, Revenue ($m), 2006-2011 40
  • Figure 30: Acute Respiratory Distress Syndrome Therapeutics Market, Japan, Forecast ($m), 2011-2019 41
  • Figure 31: Acute Respiratory Distress Syndrome Therapeutics, Pipeline by Phase of Development, 2012 46
  • Figure 32: Technology Trends Analytical Framework for the Acute Respiratory Distress Syndrome Pipeline, 2012 48
  • Figure 33: Technology Trends Analytical Framework for the Acute Respiratory Distress Syndrome Therapeutics Pipeline - Description, 2012 49
  • Figure 34: Acute Respiratory Distress Syndrome Therapeutics - Clinical Pipeline by Mechanism of Action, 2012 50
  • Figure 35: Acute Respiratory Distress Syndrome Therapeutics - Clinical Trials by Country, 2012 53
  • Figure 36: Acute Respiratory Distress Syndrome Therapeutics - Clinical Trials by Phase, 2012 54
  • Figure 37: Acute Respiratory Distress Syndrome Therapeutics - Clinical Trials by Status, 2011 55
  • Figure 38: Acute Respiratory Distress Syndrome Therapeutics - Overall Sponsors, 2012 56
  • Figure 39: Acute Respiratory Distress Syndrome Therapeutics - Prominent Sponsors, 2012 57
  • Figure 40: Acute Respiratory Distress Syndrome Therapeutics Clinical Trials - Company Sponsors by Phase, 2012 58
  • Figure 41: Acute Respiratory Distress Syndrome Therapeutics Market, Drivers and Restraints, 2012 59
  • Figure 42: Implications for Future Market Competition in the Acute Respiratory Distress Syndrome Therapeutics Market, 2011 60
  • Figure 43: Acute Respiratory Distress Syndrome Market - Clinical Pipeline by Company, 2012 61
  • Figure 44: GlobalData Market Size Estimation 71
  • Figure 45: GlobalData Market Forecasting Model 73
Show More
Pricing